These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 31733217)

  • 1. The 2018 AHA/ACC/Multi-Society Cholesterol guidelines: Looking at past, present and future.
    Stone NJ; Grundy SM
    Prog Cardiovasc Dis; 2019; 62(5):375-383. PubMed ID: 31733217
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lipid management beyond the guidelines.
    Robinson JG
    Prog Cardiovasc Dis; 2019; 62(5):384-389. PubMed ID: 31669499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
    Wilson PWF; Polonsky TS; Miedema MD; Khera A; Kosinski AS; Kuvin JT
    Circulation; 2019 Jun; 139(25):e1144-e1161. PubMed ID: 30586775
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
    Wilson PWF; Polonsky TS; Miedema MD; Khera A; Kosinski AS; Kuvin JT
    J Am Coll Cardiol; 2019 Jun; 73(24):3210-3227. PubMed ID: 30423394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The 2013 ACC/AHA Cholesterol Management Guideline: Clearing the Confusion from Noncontroversial Components.
    Virani SS
    Tex Heart Inst J; 2016 Aug; 43(4):313-4. PubMed ID: 27547139
    [No Abstract]   [Full Text] [Related]  

  • 6. Cardiovascular Outcomes and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: Current Data and Future Prospects.
    Duprez DA; Handelsman Y; Koren M
    Vasc Health Risk Manag; 2020; 16():403-418. PubMed ID: 33116551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes.
    Roe MT; Li QH; Bhatt DL; Bittner VA; Diaz R; Goodman SG; Harrington RA; Jukema JW; Lopez-Jaramillo P; Lopes RD; Louie MJ; Moriarty PM; Szarek M; Vogel R; White HD; Zeiher AM; Baccara-Dinet MT; Steg PG; Schwartz GG
    Circulation; 2019 Nov; 140(19):1578-1589. PubMed ID: 31475572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Associations between lower levels of low-density lipoprotein cholesterol and cardiovascular events in very high-risk patients: Pooled analysis of nine ODYSSEY trials of alirocumab versus control.
    Vallejo-Vaz AJ; Ray KK; Ginsberg HN; Davidson MH; Eckel RH; Lee LV; Bessac L; Pordy R; Letierce A; Cannon CP
    Atherosclerosis; 2019 Sep; 288():85-93. PubMed ID: 31349086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increases in statin eligibility to reduce cardiovascular risk according to the 2013 ACC/AHA cholesterol guidelines in the Africa Middle East region: a sub-analysis of the Africa Middle East Cardiovascular Epidemiological (ACE) study.
    Hamoui O; Omar MI; Raal FJ; Rashed W; Kane A; Alami M; Abreu P; Mashhoud W; Alsheikh-Ali AA
    BMC Cardiovasc Disord; 2019 Mar; 19(1):61. PubMed ID: 30876390
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Clinical Guide to Combination Lipid-Lowering Therapy.
    Russell C; Sheth S; Jacoby D
    Curr Atheroscler Rep; 2018 Mar; 20(4):19. PubMed ID: 29516190
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PCSK9 Inhibitors in Secondary Prevention-An Opportunity for Personalized Therapy.
    Board C; Kelly MS; Shapiro MD; Dixon DL
    J Cardiovasc Pharmacol; 2020 May; 75(5):410-420. PubMed ID: 32379108
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.
    Jellinger PS; Handelsman Y; Rosenblit PD; Bloomgarden ZT; Fonseca VA; Garber AJ; Grunberger G; Guerin CK; Bell DSH; Mechanick JI; Pessah-Pollack R; Wyne K; Smith D; Brinton EA; Fazio S; Davidson M
    Endocr Pract; 2017 Apr; 23(Suppl 2):1-87. PubMed ID: 28437620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of Non-Statins, LDL-C Thresholds, and Special Population Considerations: A Look at the Updated 2016 ACC Consensus Committee Recommendations.
    Adhyaru BB; Jacobson TA
    Curr Atheroscler Rep; 2017 Jun; 19(6):29. PubMed ID: 28500517
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipid update 2020 - Introduction and foreword.
    Robinson JG
    Prog Cardiovasc Dis; 2019; 62(5):373-374. PubMed ID: 31711789
    [No Abstract]   [Full Text] [Related]  

  • 15. Department of Veterans Affairs (VA) and U.S. Department of Defense (DoD) guidelines for management of dyslipidemia and cardiovascular disease risk reduction: Putting evidence in context.
    Al Rifai M; Blumenthal RS; Stone NJ; Schofield RS; Orringer CE; Michos ED; Heidenreich PA; Braun L; Birtcher KK; Smith SC; Nambi V; Grundy S; Virani SS
    Prog Cardiovasc Dis; 2021; 68():2-6. PubMed ID: 34371083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-Effectiveness of LDL-C Lowering With Evolocumab in Patients With High Cardiovascular Risk in the United States.
    Gandra SR; Villa G; Fonarow GC; Lothgren M; Lindgren P; Somaratne R; van Hout B
    Clin Cardiol; 2016 Jun; 39(6):313-20. PubMed ID: 27092712
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Counterpoint: Low-Density Lipoprotein Cholesterol Targets Are Not Needed in Lipid Treatment Guidelines.
    Robinson JG; Ray K
    Arterioscler Thromb Vasc Biol; 2016 Apr; 36(4):586-90. PubMed ID: 26988588
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Initiation Patterns of Statins in the 2 Years After Release of the 2013 American College of Cardiology/American Heart Association (ACC/AHA) Cholesterol Management Guideline in a Large US Health Plan.
    Olufade T; Zhou S; Anzalone D; Kern DM; Tunceli O; Cziraky MJ; Willey VJ
    J Am Heart Assoc; 2017 May; 6(5):. PubMed ID: 28473405
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vascular Quality of Care Assessment: Clinicians' Adherence to Lipid-Lowering Therapy for Patients with Atherosclerotic Cardiovascular Disease.
    Chan J; Rajalingam T; Fossella J; Zhou H; Eisenberg N; Roche-Nagle G
    Ann Vasc Surg; 2020 Nov; 69():197-205. PubMed ID: 32554202
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Spotlight from the American Society for Preventive Cardiology on Key Features of the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guidelines on the Management of Blood Cholesterol.
    Wong ND; Amsterdam EA; Ballantyne C; Khera A; Nasir K; Toth PP;
    Am J Cardiovasc Drugs; 2020 Feb; 20(1):1-9. PubMed ID: 31286451
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.